Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908641 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL1486163 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL29400870 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL29401170 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL3728170 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL30896130 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL31732619 | 1.00 | FABP5 (0.43) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL26314523 | 0.90 | KMT2A (0.38) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL26312165 | 0.90 | KMT2A (0.38) | FABP5FABP7KMT2ACTSLCTSB | |
| SCHEMBL30116865 | 0.90 | KMT2A (0.38) | FABP5FABP7KMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521362-B | Preparation method of Pseudodestruxin B | 哈尔滨工业大学（深圳） | 2024-05-28 | — | — | CN | claimed |
| CN-115521362-A | Preparation method of pseudodestruxinB | 哈尔滨工业大学（深圳） | 2022-12-27 | — | — | CN | claimed |
| US-20260098059-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | ENDOMET BIOSCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12441768-B2 | Compositions and methods for treating endometriosis | ENDOMET BIOSCIENCES, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| US-10414797-B2 | Gelatinase inhibitors and use thereof | IPROTEOS S.L (ES) | 2019-09-17 | — | — | US | disclosed |
| EP-3480195-A1 | METHOD FOR THE SYNTHESIS OF CYCLIC DEPSIPEPTIDES | Bayer Animal Health GmbH (DE) | 2019-05-08 | — | — | EP | disclosed |
| US-20180319839-A1 | GELATINASE INHIBITORS AND USE THEREOF | IPROTEOS S.L (ES) | 2018-11-08 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441768-B2 | Compositions and methods for treating endometriosis | CTNNB1, CTNNBL1, WNT3A | FABP5 228/4885FABP7 294/4885KMT2A 3933/4885 |
| US-10414797-B2 | Gelatinase inhibitors and use thereof | MMP8, SERPINE1, MMP9 | FABP5 1355/4885FABP7 191/4885KMT2A 4455/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | FABP5 4631/4885FABP7 4721/4885KMT2A 1250/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | FABP5 4631/4885FABP7 4721/4885KMT2A 1250/4885 |
| US-20180319839-A1 | GELATINASE INHIBITORS AND USE THEREOF | MMP8, SERPINE1, MMP9 | FABP5 1355/4885FABP7 191/4885KMT2A 4455/4885 |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | FABP5 2337/4885FABP7 4670/4885KMT2A 4176/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | FABP5 3537/4885FABP7 3487/4885KMT2A 2092/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | FABP5 4631/4885FABP7 4721/4885KMT2A 1250/4885 |
| US-20260098059-A1 | COMPOSITIONS AND METHODS FOR TREATING ENDOMETRIOSIS | NR1H2, NR1H3, CTNND1 | FABP5 125/4885FABP7 55/4885KMT2A 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.